rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    XFOR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      X4 Pharmaceuticals at Stifel 2026 Healthcare Conference: leaner path forward
      Nov 12Investing.comXFORSF
      X4 Pharmaceuticals at Guggenheim conference: all-in on mavorixafor
      Nov 10Investing.comXFOR
      X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Tops Revenue Estimates
      Nov 4Yahoo FinanceXFOR
      X4 Pharmaceuticals: Q3 Earnings Snapshot
      Nov 4Yahoo FinanceXFOR
      X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
      Nov 4Yahoo FinanceXFOR
      X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
      Nov 3Yahoo FinanceXFORJEF
      X4 Pharmaceuticals estimates 15,000-patient U.S. market for drug
      Oct 29Investing.comXFOR
      X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
      Oct 29Yahoo FinanceXFOR
      X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia
      Oct 29Yahoo FinanceXFOR
      X4 Pharmaceuticals executive chairman buys $11,883 in stock
      Oct 19Investing.comXFOR
      X4 Pharmaceuticals Secures New $150 Million Term Loan

      Detailed price information for X4 Pharmaceuticals Inc (XFOR-Q) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailXFOR
      X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
      Oct 9Yahoo FinanceXFOR
      X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures
      Oct 8Yahoo FinanceXFOR
      X4 Pharmaceuticals Enters Up to $150 Million Term Loan Facility
      Oct 8Yahoo FinanceXFOR
      X4 Pharmaceuticals secures $150M loan facility with K2HV
      Oct 8Investing.comXFOR
      X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
      Oct 8Yahoo FinanceXFOR
      X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hemat...

      Oct 1Business InsiderXFOR
      Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround

      X4 Pharmaceuticals (XFOR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

      Sep 24Yahoo FinanceXFOR
      X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

      X4 Pharmaceuticals (XFOR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

      Sep 11Yahoo FinanceXFOR
      X4 Pharmaceuticals at Wells Fargo conference: trial reset lifts outlook
      Sep 10Investing.comXFORWFC
      Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Jazz Pharmaceuticals (JAZZ)

      Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailXFOR
      X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

      BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on Thursday, September 10, 2026 at 9:30 a.m. ET. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations. About X4 Pharmaceuticals X4 Pharmac

      Sep 9Yahoo FinanceXFORWFC
      X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

      - FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial - - Expect Completion of Enrollment by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the positive outcome of its Type C Meeting with the U.S. Food and Drug Administration (FDA) related to the global 4WARD Phase 3 clinical trial. The pu

      Sep 8Yahoo FinanceXFOR
      X4 Pharmaceuticals Reaches FDA Agreement on Revised Phase 3 Trial for Chronic Neutropenia Treatment
      Sep 8Yahoo FinanceXFOR
      X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Sep 1Yahoo FinanceXFOR

      This is the newest page. Registered accounts read further back.